Simple, convenient and safe, vaginal pessaries are among the most sought-after and appreciated solutions for the treatment of pelvic organ prolapse (POP) and urinary incontinence.
The global size of the pessary market was estimated at US $239.9 million in 2020 and weighs 6.4% on the global medical device market, valued at US $373 billion.
Among the main factors contributing to the growth of the market, estimated at a CAGR of 9.2% from 2021 to 2028, there is an increasing prevalence of pelvic organ prolapse (POP), a growing geriatric population and therefore more prone to POP, easy product availability, a change in lifestyle and a rapid evolution of non-invasive treatment options that avoid corrective surgery. Especially during the COVID-19 pandemic, pessaries were among the most chosen solutions as a temporary measure compared to corrective surgeries, which suffered significant delays.
(Source: https://www.grandviewresearch.com/industry-analysis/vaginal-pessary-market-report )
The Food Drug Administration (FDA) predicts that the number of women with POP will increase by 46% by 2050, reaching 4.9 million.
As for stress urinary incontinence, another condition that requires the use of a pessary, is greater in women with a poor nutritional status which leads to a weakening of the pelvic muscles, especially the bladder.
Urinary incontinence affects 25-45% of women globally and the population exposed to it is growing significantly, especially in those countries where the average age is increasing, such as Belgium.
Uro-gynecological screening, targeted physiotherapy and non-invasive treatments, such as pessaries, are ways to prevent POP problems and urinary incontinence.